# EDGAR Filing Document

**Accession Number:** 0000879169
**File Stem:** 0000879169-26-000016
**Filing Date:** 2026-3
**Character Count:** 10581
**Document Hash:** 55d43bf5c7ca4e8699d3284764b5674f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000879169-26-000016.hdr.sgml**: 20260326

**ACCESSION NUMBER**: 0000879169-26-000016

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260325

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260326

**DATE AS OF CHANGE**: 20260326

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INCYTE CORP
- **CENTRAL INDEX KEY:** 0000879169
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 943136539
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12400
- **FILM NUMBER:** 26794487

**BUSINESS ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803
- **BUSINESS PHONE:** 3024986700

**MAIL ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE CORP
- **DATE OF NAME CHANGE:** 20030318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE GENOMICS INC
- **DATE OF NAME CHANGE:** 20000710

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19930902

?xml version='1.0' encoding='ASCII'? incy-20260325

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 25, 2026

**INCYTE CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-12400** | **94-3136539** |
| (State or Other Jurisdiction of<br>Incorporation) | (Commission File Number) | (I.R.S. Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **1801 Augustine Cut-Off**<br>**Wilmington, DE** | **19803** |
| (Address of principal executive offices) | (Zip Code) |

---

**(302) 498-6700**

(Registrant's telephone number,

including area code)

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of exchange on which registered** |
| Common Stock, $.001 par value per share | INCY | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 (§ 240.12b—2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 25, 2026, Incyte Corporation (the "Company") announced title changes for certain current members of its executive leadership team, effective immediately. Pablo J. Cagnoni's title was changed to President, Incyte and Global Head of Research and Development; Steven H. Stein's title was changed to Executive Vice President, Chief Medical Officer and Head of Late-stage Development; and Mohamed Issa's title was changed to Executive Vice President and Head of U.S. Commercial. Dr. Cagnoni replaces William J. Meury as President, Incyte. Mr. Meury remains Chief Executive Officer and a member of the Company's Board of Directors. Mr. Meury, Dr. Cagnoni, Dr. Stein and Dr. Issa are collectively referred to herein as the "Impacted Executives".

There were no changes to the compensation arrangements between the Company and any Impacted Executive in connection with these title changes. Further biographical information and a description of the business experience of each of the Impacted Executives is contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on February 10, 2026, which are incorporated herein by reference.

A copy of the Company's press release announcing the title changes is attached as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibits** | **Description** |
| 99.1 | [Press release issued by Incyte Corporation dated March 25, 2026.](march2026titlechanges-ex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBLR document). |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 26, 2026 |  |  |
|  | INCYTE CORPORATION | INCYTE CORPORATION |
|  | By: | /s/ Richard Hoffman |
|  |  | Richard Hoffman |
|  |  | Executive Vice President and General Counsel |

---

## Exhibit 99.1

**Exhibit 99.1**

![incy-20220802xex99d1001a.jpg](incy-20220802xex99d1001a.jpg)

**FOR IMMEDIATE RELEASE**

**Incyte Announces Executive Leadership Appointments**

**WILMINGTON, Del. – March 25, 2026** – Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company's strategic focus and long-term growth plans.

Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni's scientific leadership, Incyte's R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive.

Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte's extensive and growing late stage development programs across Hematology, Oncology and Immunology as well as Global Medical Affairs, a critical capability for data generation and reinforcing the Company's scientific leadership throughout the healthcare community. A highly respected leader at Incyte for more than a decade, Dr. Stein's scientific judgment, development expertise and patient-centric approach have been instrumental to the Company's success.

Mohamed Issa, Pharm.D. has been appointed Executive Vice President and Head of U.S. Commercial. In this role, Mr. Issa will continue to oversee the U.S. Oncology business while assuming expanded responsibility for U.S. Immunology. These business units are being integrated into a single U.S. commercial organization to support strategic alignment and execution for new product launches, operational effectiveness and standardization of best practices. Mr. Issa is an experienced executive with a proven track record in new product launch planning and operations across both Oncology and Immunology, and his execution-oriented approach will be critical to sustain commercial performance at Incyte.

"These appointments reflect the significant contributions Pablo, Steven and Mohamed have made to Incyte and the value they continue to bring to the company," said Bill Meury, Chief Executive Officer, Incyte. "Additionally, we are confident that integrating our U.S. commercial teams into one organization will drive effective launch execution and position Incyte for long-term success."

As part of the transition, Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period.

For more background on Incyte's Leadership Team, please visit https://incyte.com/our-company/our-leadership.

**About Incyte®**

Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

------

**Forward-Looking Statements**

Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including any discussion of the strength of Incyte's enterprise leadership and Incyte's potential for future growth and long-term success.

These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, as detailed in Incyte's reports filed with the Securities and Exchange Commission, including its annual report on form 10-K for the year ended December 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements.

\# \# \#

**<u>Contacts</u>**

---

| | |
|:---|:---|
| **Media** | **Investors** |
| media@incyte.com | ir@incyte.com |

---